Clinical trial
Phase 1 Study of Quizartinib
NCT02675478 · Daiichi Sankyo Co., Ltd., Industry · Completed
Key facts
| NCT number | NCT02675478 |
|---|---|
| Title | Phase 1 Study of Quizartinib |
| Official title | A Phase 1, Open-Label, Dose Escalation Study of Quizartinib, An Oral FLT3 Inhibitor, in Japanese Patients With Relapsed or Refractory Acute Myeloid Leukemia |
| Lead sponsor | Daiichi Sankyo Co., Ltd., Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Relapsed AML, Refractory AML |
| Intervention type | Drug |
| Interventions | AC220 |
| Enrollment | 17 |
| Start date | Feb 1, 2016 |
| Primary completion | Nov 13, 2018 |
| Completion | Nov 13, 2018 |
| First posted | Feb 5, 2016 |
| Last update posted | Feb 12, 2019 |
| Countries | Japan |
At a glance
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: